Newsbenzinga
Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote
· Published
Article summary
FDA advisory panel backed Replimune's RP1 melanoma data ahead of the agency's August 2 decision despite earlier staff criticism.
An excerpt from the original article.
Comments —
Loading comments…